Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard T Bryan

Showing results (11-20 of 133) with videos related to

Pageof 14
Sort By:
BJU International|June 4, 2010
Is it time to re-design the haematuria clinic?Richard T Bryan, Michael A Wallace
European Urology|April 14, 2009
Editorial comment on: Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in FinlandRichard T Bryan, Maurice P Zeegers
European Urology|March 12, 2015
Words of wisdom. Bladder cancers arise from distinct urothelial sub-populationsRichard T Bryan, Douglas G Ward
European Urology|May 14, 2014
Does the nonurologic scientific community understand urothelial bladder cancer?Richard T Bryan, Roger Kirby, Hugh Mostafid
European Urology|April 7, 2009
Have we abandoned the "superficial" in bladder cancer?Richard T Bryan, D Michael A Wallace
European Urology|August 11, 2020
Molecular Subtypes of T1 Bladder Cancer: Biomolecular Characteristics Versus Clinical UtilityDouglas G Ward, Roland Arnold, Richard T Bryan
Translational Andrology and Urology|May 8, 2018
Red patches during bladder cancer surveillance: to biopsy or not to biopsy?Ditte Drejer, Jørgen Bjerggaard Jensen, Richard T Bryan
BJU International|March 3, 2026
The nascent role of circulating tumour DNA in the management of non-muscle-invasive bladder cancerRichard T Bryan, Keval Patel, Douglas G Ward
Translational Andrology and Urology|May 21, 2026
<i>PENK</i> methylation and non-invasive bladder cancer detectionRichard T Bryan, Anshita Goel, Douglas G Ward
Translational Andrology and Urology|February 20, 2025
Balancing risks and benefits in the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancerSamantha Unsworth-White, Nada Humayun-Zakaria, Richard T Bryan
Pageof 14

Showing results (11-20 of 133) with videos related to

Sort By:
Pageof 14
BJU International|June 4, 2010
Is it time to re-design the haematuria clinic?Richard T Bryan, Michael A Wallace
European Urology|April 14, 2009
Editorial comment on: Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in FinlandRichard T Bryan, Maurice P Zeegers
European Urology|March 12, 2015
Words of wisdom. Bladder cancers arise from distinct urothelial sub-populationsRichard T Bryan, Douglas G Ward
European Urology|May 14, 2014
Does the nonurologic scientific community understand urothelial bladder cancer?Richard T Bryan, Roger Kirby, Hugh Mostafid
European Urology|April 7, 2009
Have we abandoned the "superficial" in bladder cancer?Richard T Bryan, D Michael A Wallace
European Urology|August 11, 2020
Molecular Subtypes of T1 Bladder Cancer: Biomolecular Characteristics Versus Clinical UtilityDouglas G Ward, Roland Arnold, Richard T Bryan
Translational Andrology and Urology|May 8, 2018
Red patches during bladder cancer surveillance: to biopsy or not to biopsy?Ditte Drejer, Jørgen Bjerggaard Jensen, Richard T Bryan
BJU International|March 3, 2026
The nascent role of circulating tumour DNA in the management of non-muscle-invasive bladder cancerRichard T Bryan, Keval Patel, Douglas G Ward
Translational Andrology and Urology|May 21, 2026
<i>PENK</i> methylation and non-invasive bladder cancer detectionRichard T Bryan, Anshita Goel, Douglas G Ward
Translational Andrology and Urology|February 20, 2025
Balancing risks and benefits in the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancerSamantha Unsworth-White, Nada Humayun-Zakaria, Richard T Bryan
Pageof 14